Login to Your Account

Clinic Roundup

Wednesday, January 25, 2012
• Immatics Biotechnologies GmbH, of Tuebingen, Germany, reported Phase II data showing IMA910 was able to stimulate relevant immune responses against the tumor-associated peptides (TUMAPs) in the majority of vaccinated patients with advanced and/or metastatic colorectal cancer who had shown no progression following 12 weeks of first-line oxaliplatin-based chemotherapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription